Predictive Oncology Inc. POAI Archives - Page 10 of 19

FridayAug 14, 2020 11:12 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Q2 2020 Results, Business Update and DojoLIVE! Interview

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Thursday released financial results for the quarter ended June 30, 2020 and provided a business update. “During the second quarter we reached a major milestone in our journey towards full commercialization with the first sale of our novel ovarian cancer cell media to a top-rated medical university in New England,” Dr. Carl Schwartz, Predictive Oncology CEO, stated in the news release. "This sale serves as a solid proof point of our mission and is a significant achievement towards improving healthcare…

TuesdayAug 11, 2020 1:14 pm

Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Members; Adds Depth of Knowledge, Experience to Strengthen Company’s Vision

Appointments signify POAI’s commitment to aligning board’s expertise with company’s strategic vision Board members to support development, commercialization of unique offering that improves outcomes for oncology patients, value to shareholders New appointments effective immediately Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, announced the appointment of three new highly qualified individuals to its board of directors (http://ibn.fm/gezoD). The three new board members — Dr. Nancy Chung-Welch, PhD; Charles L. Nuzum, CPA; and Greg St. Clair — bring with them more than a century of invaluable experience in business development, marketing and financial expertise in…

TuesdayAug 11, 2020 11:01 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Shareholder Letter Highlights Achievements, Discusses Two Key Proposals

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, outlined the company’s recent accomplishments in a letter released to shareholders. The letter, sent from CEO Dr. Carl Schwartz, also summarized voting recommendations from POAI’s Board of Directors regarding two proposals that are scheduled for shareholder vote next month. “Predictive Oncology is committed to executing our strategic vision to develop and commercialize an offering that will enable us to support the improvement in healthcare outcomes for oncology patients and increase value for our shareholders,” stated Schwartz in a press release containing…

FridayAug 07, 2020 1:23 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Marks Milestone in Applying AI to Find New Targets for Treatment, Diagnostics

Predictive Oncology (NASDAQ: POAI), through its subsidiary TumorGenesis and working with distributor US Biological Corporation, has accomplished a major achievement. Recently, the company announced its first-ever commercial order of a novel ovarian cancer cell culture media for cancer cells collected from patient-derived samples (“PDx”) (http://ibn.fm/2xwl6). An article discussing this quotes Richard Gabriel of TumorGenesis, who states, “Capturing and culturing and then being able to study ovarian cancer cell types has always been limited by the ability to grow reproducible cultures that reflect what is in the patient. We now have isolated and grown 25 ovarian cancer cell types, 11 of that…

MondayAug 03, 2020 11:41 am

Predictive Oncology Inc. (NASDAQ: POAI)’s TumorGenesis Presents at Precision in Drug Discovery & Preclinical Virtual Summit

TumorGenesis president Richard Gabriel selected to feature as keynote presenter at inaugural Drug Discovery & Preclinical Virtual Summit The summit features over 150 delegates from across bio-pharmaceutical industry coming together to market sector’s latest breakthroughs TumorGenesis, which specializes in creating laboratory-grown cancer cells directed towards ovarian cancer research, recently announced its first sale of cancer cell culture media to US university The global cell culture media market set to grow to over $2.4 billion per annum by 2024 Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and…

ThursdayJul 30, 2020 2:01 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) to Integrate Proprietary Database with CoRE to Drive Drug Discovery, Development

Predictive Oncology (NASDAQ: POAI) has completed a strategic move to accelerate commercialization of its proprietary artificial intelligence “AI”-driven drug discovery and development. A recent article discussing Predictive Oncology’s recent acquisition of Quantitative Medicine (“QM”), a biomedical analytics and computational biology company, quotes POAI CEO Dr. Carl Schwartz, where he states, “This acquisition will enable us to further leverage our unique database of drug-response and genomics profiles that our subsidiary, Helomics, has gathered from more than 150,000 cancer cases over more than 10 years of clinical testing. Integrating QM’s proven machine-learning platform, CoRE, with our proprietary database of drug response and…

ThursdayJul 30, 2020 12:17 pm

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Announces First Commercial Sale of Unique Ovarian-Cancer-Cell Media

POAI’s TumorGenesis inks deal with top-rated medical university in New England Predictive’s proprietary media allows researchers around the world to isolate, culture ovarian cancer cell types, leading to new targets for treatment The TumorGenesis media retain more than 95% of the DNA and RNA as well as crucial proteomic signatures Predictive Oncology (NASDAQ: POAI) has sold its first-ever commercial order of its novel ovarian cancer cell culture media for cancer cells collected from patient-derived samples (“PDx”) (http://ibn.fm/2xwl6). The sale, made through POAI’s subsidiary TumorGenesis working with distributor US Biological Corporation, marks a milestone for the knowledge-driven company, which is focused on…

WednesdayJul 22, 2020 1:21 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) on ‘Cash Runway’ to Fund Key Milestones

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is on a well-funded path to move forward with its goals. A recent article discussing this quotes POAI CEO Dr. Carl Schwartz, who states, “[POAI] improved our liquidity position and streamlined our capital structure with the conversion of a $2.1 million convertible note, previously held by me, to newly issued equity. This action demonstrates my confidence in the commercial viability of our work, and when combined with the additional capital we raised through an equity offering, provides us with the cash…

WednesdayJul 22, 2020 11:23 am

Predictive Oncology Inc. (NASDAQ: POAI) Finalizes Acquisition Deal Expected to Revolutionize Role of AI-Driven Predictive Models

POAI completes acquisition designed to accelerate commercialization of proprietary AI-driven drug discovery, development Strategic move allows for one-of-a-kind, end-to-end ‘discovery machine’ that can rapidly generate potential therapeutic candidates Company to offer new capability to pharmaceutical company customers in revenue-generating projects later this year Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, has completed its acquisition of Quantitative Medicine (“QM”) (http://ibn.fm/vqmwL). POAI signed a letter of intent to acquire QM, a biomedical analytics and computational biology company, in January (http://ibn.fm/4iRTV). The strategic move should accelerate the commercialization of Predictive Oncology’s proprietary AI-driven drug discovery…

TuesdayJul 14, 2020 11:03 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces New Board Appointments

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the appointment of three new members to the company’s board of directors, effective immediately. According to the update, joining the board as independent directors are: Dr. Nancy Chung-Welch, Ph.D., Charles L. Nuzum, CPA and Greg St. Clair. “These appointments signify our absolute commitment to aligning our Board’s expertise with the company’s strategic vision of developing and commercializing an offering that will enable us to support the improvement in healthcare outcomes for oncology patients and increase value to our shareholders,”…

Site Search

Company Search

Tag: Predictive Oncology Inc. POAI